Fabio Chianelli
Director Ejecutivo en PHARMATHER HOLDINGS LTD. .
Fortuna: 3 M $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Carlo Sansalone | M | - | 10 años | |
Christian Scovenna | M | 50 | 5 años | |
Michael Frank | M | - | 5 años | |
William Jackson | M | - |
Revive Therapeutics, Inc.
Revive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Revive Therapeutics Ltd., Revive Therapeutics, Inc. is a specialty life sciences company based in North York, CA. The company focuses on the research and development of therapeutics for rare disorders and infectious diseases. Revive Therapeutics' cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. Revive Therapeutics was acquired by Mercury Capital II Ltd. on January 06, 2014 for $4.67 million. The Canadian company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is also exploring the use of bucillamine for the potential treatment of infectious diseases, including COVID-19. The company was founded by Fabio Chianelli. Revive recently acquired Psilocin Pharma Corp. to advance psilocybin-based therapeutics in various diseases and disorders. | 10 años |
Ming Jang | M | 63 | 2 años | |
Carmelo Marrelli | M | 53 |
Revive Therapeutics, Inc.
Revive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Revive Therapeutics Ltd., Revive Therapeutics, Inc. is a specialty life sciences company based in North York, CA. The company focuses on the research and development of therapeutics for rare disorders and infectious diseases. Revive Therapeutics' cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. Revive Therapeutics was acquired by Mercury Capital II Ltd. on January 06, 2014 for $4.67 million. The Canadian company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is also exploring the use of bucillamine for the potential treatment of infectious diseases, including COVID-19. The company was founded by Fabio Chianelli. Revive recently acquired Psilocin Pharma Corp. to advance psilocybin-based therapeutics in various diseases and disorders. | 11 años |
Beverly Incledon | M | - | 4 años | |
Andrew Lindzon | M | 63 | 5 años | |
Jing Peng | M | 47 | 3 años | |
Joshua Herman | M | - | 5 años | |
Elyssia Patterson | F | 38 | 3 años | |
Owen van Cauwenberghe | M | - | - | |
Andrew Newbury | M | - | - | |
Bassma Ghali | M | - | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Craig Leon | M | 56 | 6 años | |
Emily Davis | F | 52 | 2 años | |
Robbie Grossman | M | 50 | 3 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Canadá | 17 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Fabio Chianelli
- Red Personal